Efficacy and Safety of Canagliflozin in Patients with Type II Diabetes Mellitus Inadequately Controlled on Triple Drug Therapy.
Conclusion: Canagliflozin 100 mg (One tablet) administered to patients in addition to the inadequately controlled triple drug OHAs who were reluctant for an insulin therapy provided a significant reduction in HbA1c and body weight over 12 weeks. Canagliflozin a SGLT 2 inhibitor is a promising new drug in patients with T2DM in patients who are inadequately controlled on triple therapy and are reluctant to insulin therapy.
PMID: 31571450 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
More News: Canagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | General Medicine | India Health | Insulin | Invokana | SGLT2 Inhibitors | Sodium | Study | Urinary Tract Infections | Weight Loss